國外演講紀錄
92. Molecular pathology of neuroendocrine tumors (Updates in Neuroendocrine Tumors, the 29th World Congress of World Association of Societies of Pathology and Laboratory Medicine; Kyoto International Conference Center; November 16, 2017)
91. Current and emerging approaches in molecular testing o NSCLC (Le Méridien Chiang Mai; April 29, 2017)
90. The application of biomarkers for the diagnosis and treatment of neuroendocrine tumor (Jingling Hotel Nanjing, China; July 9, 2016)
89. Lung NET Pathology: WHO 2015 Classification of Lung NET (Park Hotel Alexandra, Singapore; June 25, 2016)
88. Molecular profiling and management of pulmonary neuroendocrine tumor (3rd Conference of the Asia-Pacific Neuroendocrine Tumour Society, G-Hotel, Penang; October 30, 2015)
87. Primary cutaneous analplastic large cell lymphoma (Institute for Biomedical Research Marqués de Valdecilla; Santander-Hospital Universitario Marqués de Valdecilla, Santander, Spain; November 18, 2015)
86. Heterogeneity and Diagnosis in Asia (Next Generation Precision Medicine, APECHO meeting; Taipei, Taiwan; October 18, 2015)
85. Differential Diagnosis: GIST vs. other sarcomas (Marco Polo Hotel, Manila, Philippines; August 27, 2015)
84. NET Pathology Report: A Critical Tool in the Management of NET Patients (Marco Polo Hotel, Manila, Philippines; August 27, 2015)
83. The current status of pathology diagnosis of GIST in Taiwan (Shijiazhuang, Beijing; December 14, 2014)
82. The certification of a lab, from one centre experience (Hotel Jumeirah Himalayas, Shanghai, China; November 2, 2014)
81. Molecular Basis and Clinical Implication of NET (International Congress of Pathology and Laboratory Medicine; Shangri-La Hotel, Kuala Lumpur; August 28, 2014)
80. Molecular basis, differential diagnosis, and risk stratification of GIST (International Congress of Pathology and Laboratory Medicine; Shangri-La Hotel, Kuala Lumpur; August 28, 2014)
79. The key role of Pathologist in Improving Diagnosis of NETs (International Congress of Pathology and Laboratory Medicine; Shangri-La Hotel, Kuala Lumpur; August 28, 2014)
78. Preparing for Tomorrow: Molecular Diagnostics and the Changing NSCLC Landscape (Mulia Hotel, Jakarta; November 24, 2013)
77.m Novel Oncogenic Driver Mutation : Identification of EML4–ALK fusion Gene in NSCLC (Mulia Hotel, Jakarta; November 24, 2013)
76. Molecular basis of neuroendocrine tumor (APNETS Conference Kuala Lumpur; Le Meridien Kuala Lumpur, Malaysia; October 27, 2013)
75. How can we define Luminal A by ER, PR, Her2 and Ki-67? (Targeting the Right Approach in Management of Pre-Menopausal Early Breast Cancer; Four Season Hotel, Singapore; August 30, 2013)
74. Diagnostic Clues to Classifying the Right Patients Subtypes (Targeting the Right Approach in Management of Pre-Menopausal Early Breast Cancer; Four Season Hotel, Singapore; August 30, 2013)
73. Intrinsic Subtypes in Breast Cancer (St Gallen): Identification, Clinical Implication & Standardization (Lotte Hotel World; June 15, 2013)
72. Improving GIST management by mutational analysis (GISTour ‘13; Hilton, Nanjing; April 21, 2013)
71. Diagnostics and pathology markers for the treatment of GIST (GISTour ’13; Hilton, Nanjing; April 21, 2013)
70. Improving GIST management by mutational analysis (GISTour ’13; Sofitel Guangzhou Sunrich, Guangzhou; April 20, 2013)
69. Diagnostics and pathology markers for the treatment of GIST (GISTour ‘13; Sofitel Guangzhou Sunrich, Guangzhou; April 20, 2013)
68. NET Pathological Diagnosis (The 2nd NET Forum; Sanya, China; November 25, 2012)
67. The significance and limitations of genetic test (The Second China GIST Consensus Committee of Experts Plenary Session & 2012 Novartis GIST Summit Forum; Chengdu, China; November 24, 2012)
66. Molecular Profiling of GIST: Taiwan experience (One world hotel, Kuala Lumpur, Malaysia; November 3, 2012)
65. Personalized medicine in Oncology: NET (Shangri-La Hotel, Chiang Mai, Thailand; August 11, 2012)
64. NET: Diagnostic conundrums from two different perspectives (InterContinental Kuala Lumpur Hotel, Kuala Lumpur, Malaysia; July 7, 2012)
63. NET Pathology Preceptorship (Le meridien, Taipei; June 28-29, 2012)
62. Molecular basis and pathology classification of NET (Asian Society of Clinical Oncology; June 15, 2012; Seoul, Korea)
61. Clinical evaluation consideration for affordable access IVDs (Conference of Regulatory Convergence for IVDs, Co-sponsored by Taiwan Food and Drug Administration, London School of Hygiene and Tropical Medicine, and Bill & Melinda Gates Foundation; W Hotel, Taipei; May 18, 2012)
60. NET: Address to the current challenges (Hotel Taj Mahal, Delhi, India, January 28-29, 2012)
59. Historical, Molecular and Clinical Aspects of NET (Malaysia Society of Pathology; Le Meridien Hotel, Kuala Lumpur, Malaysia; December 4, 2011)
58. WHO NET Classification 2010: Grading and Staging (Malaysia Society of Pathology; Le Meridien Hotel, Kuala Lumpur, Malaysia; December 4, 2011)
57. QA & QC of Molecular Pathology (Malaysia Society of Pathology; Le Meridien Hotel, Kuala Lumpur, Malaysia; December 3, 2011)
56. A Molecular Approach in Diagnosis: Redefining GIST (Malaysia Society of Pathology; Le Meridien Hotel, Kuala Lumpur, Malaysia; December 3, 2011)
55. WHO Classification of GIST: Advance/Unresectable GIST (Malaysia Society of Pathology; Le Meridien Hotel KL, Kuala Lumpur, Malaysia; December 3, 2011)
54. Molecular pathology of GIST (Seoul, Korea; November 18, 2011)
53. Diagnosis and Classification of NET (Bueos Aires, Argetina; October 27, 2011)
52. Diagnosis and Classification of NET (Porto Alegre, Brazil; October 25, 2011)
51. Histopathology and classification of NETs – WHO Criteria (Hong Kong; October 10, 2011)
50. Diagnosis of NET (Hong Kong; October 9, 2011)
49. Molecular pathology of NET (Tokyo, Japan; September 17, 2011)
48. Molecular pathology of NET (Bangkok, Thailand; September 16, 2011)
47. NET & GIST Pathology Masterclass (Hyatt Hotel, Taiwan; June 16-17; Taipei, Taiwan)
46. What's new for GIST: current update in pathology (May 24, APIAP, Taiwan)
45. Update of International Classification in GIST (9th International Gastric Cancer Congress; April 21; Seoul, Korea)
44. NET Pathological Assessment (NETour; Shanghai, China; April 2, 2011)
43. Case Sharing and Comments on NET (Shanghai, China; April 2, 2011)
42. NET Pathological Assessment (NETour; Beijing, China; April 1, 2011)
41. Diagnosis and Classification of NET (Asia Pancreatic NETwork; Chengdu, China; March 25, 2011)
40. Pathologic, molecular, and clinical aspects of NET (Malaysia Society of Pathology; Le Meridien Hotel, Kuala Lumpur, Malaysia; November 28, 2010)
39. Pathologic, molecular, and clinical aspects of GIST (Malaysia Society of Pathology; Le Meridien Hotel, Kuala Lumpur, Malaysia; November 27, 2010)
38. Grading, staging, classification, and biomarker of NET (GIST & NET: A multidisciplinary Journey; Hilton Hotel, Kuala Lumpur, Malaysia; August 8, 2010)
37. Pathology of GIST and Stratification for Management (GIST & NET: A multidisciplinary Journey; Hilton Hotel, Kuala Lumpur, Malaysia; August 8, 2010)
36. Grading, Staging, and Classification of NET (Selective Target, Tailored Therapy in Oncology; JW Marriott Hotel Hong Kong; July 11, 2010)
35. NETs of the GI tract (Meeting of minds excellence in NET pathology; Swissotel The Bosphorus, Istanbul, Turkey; June 20, 2010)
34. Classification of NETs (Meeting of minds excellence in NET pathology; Swissotel The Bosphorus, Istanbul, Turkey; June 19, 2010)
33. Diagnostic approach to NETs (Meeting of minds excellence in NET pathology; Swissotel The Bosphorus, Istanbul, Turkey; June 19, 2010)
32. NET tumor board (Westin Paris, Paris; November 8, 2009)
31. Addressing current unmet needs in the classification of neuroendocrine tumor (Westin Paris, Paris; November 7, 2009)
30. Neuroendocrine tumor: diagnosis and Prognosis (2009 Asia-Pacific Summit, Taiwan; July 12, 2009)
29. Pathology of gastroenteropancreatic neuroendocrine tumours - Forging a common language (Asia Oncology Summit, The Lancet Oncology and Singapore Society of Oncology; Suntec Singapore; Apr. 4, 2009)
28. Recent update of GIST diagnostics (Indonesian Pathologist Society; Cipto Mangunkusumo Hospital, Jakarta; Mar. 14, 2009)
27. Concept and Diagnosis of Neuroendocrine Tumors (Indonesian Pathologist Society; Cipto Mangunkusumo Hospital, Jakarta; Mar. 14, 2009)
26. Molecular motif as a common language in neuroendocrine tumor (NET Pathology Summit, National Cancer Institute; Fontainebleau Hotel, Miami Beach, Florida, USA; Feb. 7-8, 2009)
25. Clinical implications of primary and secondary mutations in GIST and pathologic risk stratification of GIST (2008 Korean GIST, Multidisciplinary Symposium; Seoul, Nov 29, 2008)
24. Mutational analysis of gastrointestinal stromal tumor (Global advisory board of GIST, Madrid, Spain; Nov 7, 2008)
23. Overview of NET: historical advancement and pathologic diagnosis (2008 Novartis Oncology Asia Pacific NET Advisory Board Meeting; Grand Hyatt Taipei, Taipei, Taiwan; Nov 1, 2008)
22. Molecular Basis and Pathological Diagnosis of Gastrointestinal stromal tumor (Gastrointestinal System Pathology; Antalya, Turkey; Oct 26, 2008 )
21. Insights into the pathophysiology of GIST and current issues in diagnosis (Novartis Oncology Asia Pacific Summit 2008, Phuket Island, Thailand, July 12, 2008)
20. Pathology of NET (Rare Gastrointestinal Tumors Symposium; Intercontinental Dubai Festival City, Dubai; Jun 14, 2008)
19. Pathology of GIST (Rare Gastrointestinal Tumors Symposium; Intercontinental Dubai Festival City, Dubai; Jun 13, 2008)
18. Mitochondrial mutation in carcinogenesis (The 2nd International Conference, Taiwan Society for Mitochondrial Research and Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan; Feb. 17, 2008)
17. Updates on Gastrointestinal Stromal Tumors (The College of Pathologists, Academy of Medicine of Malaysia; PJ Hilton, Petaling Jaya, Malaysia; April 15, 2007)
16. Potential of Kremezin carbon. (Kureha Corp., Tokyo, Japan; February 5, 2007)
15. Molecular Basis and Clinical Implication of GIST (Optimizing Medical Management of GIST in the Imatinib Era; The Regent Singapore, Singapore; November 11, 2006)
14. Mechanism and role of Mitochondrial mutation in human cancer (Mitochondria and life 2005, Toshi Center Hotel, Tokyo, Japan, December 16, 2005)
13. GIST: Case Study (Regal International East Asia Hotel; Shanghai, China; August 20, 2005)
12. GIST diagnostic definition (Regal International East Asia Hotel; Shanghai, China; August 20, 2005)
11. INTUIT Workshop, GIST-NET: from Diagnosis to Therapy (Regal International East Asia Hotel; Shanghai, China; August 20, 2005)
10. GIST- where do we stand? (Pan Asia Pacific Oncology Summit, Prince Hotel, Chiba, Japan; July 9, 2005）
9. GIST/NET: where do we stand? (GI Forum; Hong Kong Society of Clinical Oncology and Hong Kong College of Radiologists; Grand Hyatt, Hong Kong; July 7, 2005)
8. GIST in Asia Pacific and current issues in diagnosis (1st Meeting of the Asia Pacific GI Molecular Target Therapy Group; JW Marriott Hotel, Shanghai, China; January 21, 2005)
7. Recent findings and new insights in gastrointestinal stromal tumor (China Society of Pathology; Oversea Chinese Hotel, Guangzhou, China; Dec.23, 2004)
6. The target therapy without an apparent target: analysis of CD117-negative GISTs (The 11th Sino-Japan Symposium on Cancer Treatment; Taipei Veterans General Hospita, Taipei, Taiwan l; Oct. 9, 2004)
5. Target Therapy without an apparent target: Can Imatinib be used in CD117-negative GIST? (Malaysian Oncological Society; Evening Symposium; Hotel Istana, Kuala Lumpur, Malaysian; October 1, 2004)
4. Evolving Role of Molecularly Targeted Therapy (Malaysian Oncological Society; Plenary Session; Hotel Istana, Kuala Lumpur, Malaysian; October 1, 2004)
3. View of a Pathologist – Management of a GIST Patient (JW Marriott Phuket Resort and SPA, Phuket, Thailand; May 5, 2004)
2. Evolutional analysis in determining pathogenic versus nonpathogenic mutations of ATPase 6 in human mitocondriopathy (the 2nd conference of Asian Society for Mitochondrial Research and Medicine [ASMRM]; Taipei International Convention Center, Taipei, Taiwan; April 1, 2004)
1. The diagnostic standard of GIST in Taiwan (Bo’ao, Hainan Island, China; February 19, 2004)